pubmed-article:17286608 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17286608 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
pubmed-article:17286608 | lifeskim:mentions | umls-concept:C1522690 | lld:lifeskim |
pubmed-article:17286608 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
pubmed-article:17286608 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:17286608 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:17286608 | pubmed:dateCreated | 2007-3-23 | lld:pubmed |
pubmed-article:17286608 | pubmed:abstractText | Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy. Several salvage therapies have been explored, but the optimal combination regimen has not been defined. We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide-dexamethasone alone or the combination thalidomide-dexamethasone-liposomal pegylated doxorubicin. | lld:pubmed |
pubmed-article:17286608 | pubmed:language | eng | lld:pubmed |
pubmed-article:17286608 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17286608 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17286608 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17286608 | pubmed:month | Apr | lld:pubmed |
pubmed-article:17286608 | pubmed:issn | 0902-4441 | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:LeoniPietroP | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:OffidaniMassi... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:CorvattaLaura... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:BoccadoroMari... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:PalumboAntoni... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:BringhenSaraS | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:FalcoPatrizia... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:MarconiMonica... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:PiersantelliM... | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:AvontoIlariaI | lld:pubmed |
pubmed-article:17286608 | pubmed:author | pubmed-author:PolloniClaudi... | lld:pubmed |
pubmed-article:17286608 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17286608 | pubmed:volume | 78 | lld:pubmed |
pubmed-article:17286608 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17286608 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17286608 | pubmed:pagination | 297-302 | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:meshHeading | pubmed-meshheading:17286608... | lld:pubmed |
pubmed-article:17286608 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17286608 | pubmed:articleTitle | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. | lld:pubmed |
pubmed-article:17286608 | pubmed:affiliation | Clinica di Ematologia Polo Ospedaliero-Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy. m.offidani@ao-umbertoprimo.marche.it | lld:pubmed |
pubmed-article:17286608 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17286608 | pubmed:publicationType | Comparative Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17286608 | lld:pubmed |